NeuroDerm Overview

NeuroDerm developed ND0601, the first ever levodopa (L-DOPA) skin patch for Parkinson’s disease. This passive, non-invasive system is based on a proprietary L-DOPA ester formulation. ND0601 is able to achieve continuous delivery of L-DOPA, an objective that was long considered the “holy grail” of Parkinson’s disease treatment.

By overcoming the short half life of orally administered L-Dopa, the...More»

NeuroDerm developed ND0601, the first ever levodopa (L-DOPA) skin patch for Parkinson’s disease. This passive, non-invasive system is based on a proprietary L-DOPA ester formulation. ND0601 is able to achieve continuous delivery of L-DOPA, an objective that was long considered the “holy grail” of Parkinson’s disease treatment.

By overcoming the short half life of orally administered L-Dopa, the company hopes to minimize or even reverse some of the disabling late motor complications associated with the current L-DOPA oral administration. Moreover, by providing newly diagnosed patients with low, continuous levels of L-Dopa the company hopes to be able to prevent or significantly delay the later emergence of dyskinesia and other late stage motor complications. ND0601 has already entered clinical and regulatory development and the company hopes to eventually be able to offer a solution to motor complications affecting millions of PD patients.«Less